These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23100119)

  • 1. Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan.
    Ward MA; Xu Y; Viswanathan HN; Stolshek BS; Clay B; Adams JL; Kallich JD; Fine S; Saag KG
    Osteoporos Int; 2013 Apr; 24(4):1195-206. PubMed ID: 23100119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
    Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
    J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
    Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
    BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
    Olsen KR; Hansen C; Abrahamsen B
    Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and management of males with closed fractures.
    Brenneman SK; Yurgin N; Fan Y
    Osteoporos Int; 2013 Mar; 24(3):825-33. PubMed ID: 22776864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan.
    Xu Y; Viswanathan HN; Ward MA; Clay B; Adams JL; Stolshek BS; Kallich JD; Fine S; Saag KG
    J Eval Clin Pract; 2013 Feb; 19(1):50-9. PubMed ID: 21914091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between teriparatide adherence and healthcare utilization and costs in real-world US kyphoplasty/vertebroplasty patients.
    Zhao Y; Johnston SS; Smith DM; McMorrow D; Krohn K; Krege J
    Osteoporos Int; 2013 Sep; 24(9):2525-33. PubMed ID: 23529293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA).
    Landfeldt E; Ström O; Robbins S; Borgström F
    Osteoporos Int; 2012 Feb; 23(2):433-43. PubMed ID: 21286686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical costs of osteoporosis in the elderly Medicare population.
    Blume SW; Curtis JR
    Osteoporos Int; 2011 Jun; 22(6):1835-44. PubMed ID: 21165602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy.
    Modi A; Siris ES; Tang J; Sen S
    Curr Med Res Opin; 2015 Apr; 31(4):757-65. PubMed ID: 25661017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy.
    Viswanathan HN; Curtis JR; Yu J; White J; Stolshek BS; Merinar C; Balasubramanian A; Kallich JD; Adams JL; Wade SW
    Appl Health Econ Health Policy; 2012 May; 10(3):163-73. PubMed ID: 22510025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
    Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
    Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to osteoporosis medicines in Estonia-a comprehensive 15-year retrospective prescriptions database study.
    Laius O; Pisarev H; Maasalu K; Kõks S; Märtson A
    Arch Osteoporos; 2017 Dec; 12(1):59. PubMed ID: 28643266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
    Sato M; Ye W; Sugihara T; Isaka Y
    BMC Musculoskelet Disord; 2016 Nov; 17(1):489. PubMed ID: 27887655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of teriparatide adherence and persistence on fracture outcomes.
    Yu S; Burge RT; Foster SA; Gelwicks S; Meadows ES
    Osteoporos Int; 2012 Mar; 23(3):1103-13. PubMed ID: 22159748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of hip fracture prevention with vitamin D supplementation: a Markov micro-simulation model applied to the French population over 65 years old without previous hip fracture.
    Zarca K; Durand-Zaleski I; Roux C; Souberbielle JC; Schott AM; Thomas T; Fardellone P; Benhamou CL
    Osteoporos Int; 2014 Jun; 25(6):1797-806. PubMed ID: 24691648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.
    Modi A; Tang J; Sen S; Díez-Pérez A
    Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
    Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
    Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance.
    Foster SA; Foley KA; Meadows ES; Johnston JA; Wang SS; Pohl GM; Long SR
    Osteoporos Int; 2011 Feb; 22(2):551-7. PubMed ID: 20798929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.